The stock of ATAI Life Sciences N.V (ATAI) has gone up by 26.21% for the week, with a 76.87% rise in the past month and a 73.33% rise in the past quarter. The volatility ratio for the week is 3.49%, and the volatility levels for the past 30 days are 5.28% for ATAI. The simple moving average for the last 20 days is 43.57% for ATAI stock, with a simple moving average of 76.07% for the last 200 days.
Is It Worth Investing in ATAI Life Sciences N.V (NASDAQ: ATAI) Right Now?
The stock has a 36-month beta value of 1.48. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATAI is 136.80M, and at present, short sellers hold a 9.35% of that float. On June 02, 2025, the average trading volume of ATAI was 1.88M shares.
ATAI) stock’s latest price update
ATAI Life Sciences N.V (NASDAQ: ATAI) has seen a rise in its stock price by 12.55 in relation to its previous close of 2.31. However, the company has experienced a 26.21% gain in its stock price over the last five trading sessions. https://www.proactiveinvestors.com reported 2025-06-02 that Meta Platforms Inc (NASDAQ:META, ETR:FB2A, SWX:FB) is planning to let brands fully create and target ads using its artificial intelligence tools by the end of 2025, according to a report in the Wall Street Journal. Citing people familiar with the plans, the report says advertisers will be able to provide a product image and budget, and Meta’s AI will handle everything from generating the content, including text, images and video, to targeting users across Facebook and Instagram. Meta already uses AI to customise ads and suggest variations, but the new tools would go further by offering real-time personalisation based on factors like location. The company is also working on automating budget recommendations. With 3.43 billion global users across its apps, Meta sees advanced AI tools as a way to deliver ad results at scale. The move comes as rivals such as Snap, Pinterest and Reddit ramp up their own AI offerings in an increasingly competitive digital ad market. atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company’s clinical development progress in 2025, highlighting multiple upcoming trial readouts. Proactive: Hello, you’re watching Proactive. Joining me is atai Life Sciences CEO and co-founder Dr Srinivas Rao. Srinivas, very good to speak with you. You’ve had a very busy start to 2025. Let’s start off with the positive topline data of part two of the Beckley Psytech’s Phase 2a trial of BPL-003. It looks pretty encouraging. Dr Srinivas Rao: Yeah. Well, thanks for having me on. Yeah, we’re very excited by that. So this is a continuation of a Phase 2a that we reported the results on last year actually. That was a single administration of BPL-003 in folks who were not taking an SSRI at that time. This is the continuation with those patients that are currently on an SSRI. Once again, we saw very good safety and tolerability and very robust efficacy in this cohort. So certainly important data as we move forward into Phase 3 with this program. The next step here is we’re waiting for the results from the large Phase 2b trial that’s currently ongoing. And if those results are as encouraging as the ones you just mentioned, when would you be expecting to go ahead with the Phase 3 trial? I mean, we haven’t officially guided on that. And of course, the reason for that is it’s going to depend upon the results as well as discussions with the FDA. But generally speaking, we can anticipate something starting sometime next year — obviously, sort of middle of next year, perhaps a little later. So you mentioned data from the Phase 2b study, which is expected in the middle of the year. Srinivas, lots of key readouts are expected this year and going into 2026. Take us through some of the other important ones. Yeah, we’ve got quite a few coming up. So we have the BPL-003 Phase 2b that we were talking about now — that’s mid-year. RL-007, the large Phase 2b in cognitive impairment in schizophrenia, also in the middle of this year. Sort of right on top of this one, we’ll see which one comes first. And then early next year, the VLS-01 Illumina study that’s currently ongoing should be reading out as well. We just recently initiated a Phase 2a study of EMP-01 in social anxiety disorder. That too is expected to read out in the first quarter of next year. And you announced the dosing of the first patients in that EMP-01 trial. Srinivas, tell us more about the trial and what it’s targeted at? Yeah, I mean again, it’s an exploratory study. We wanted to go after a different indication. There’s really no one focused on social anxiety disorder currently with a psychedelic compound. It’s using EMP-01, which we had reported results on in January or so last year. From our Phase 1, we found some very interesting properties of that compound — specifically that it had these antiketogenic effects like MDMA, but it also had psychedelic effects as well. So, a really interesting profile — a blend of these two classes in many ways. We spent time looking for the appropriate indication for that and ultimately made the decision to move forward with social anxiety disorder. There is some limited data for MDMA in social anxiety disorder, particularly in the autism subset, where social anxiety disorder is quite prominent. We are looking at broader social anxiety disorder with this. The trial broadly is a six-week study, with two administrations of EMP-01 — on day one and then at week four — and then a readout at week six. We’re using a regulatory endpoint there, the so-called Liebowitz Social Anxiety Scale (LSAS). Again, very excited to see how this drug performs in this really important patient population, one that has a huge unmet medical need — bigger than depression — and yet has very limited options, at least from the therapeutic options for the treatment. Srinivas, apart from all of those readouts, any other milestones that your investors should be looking out for as 2025 progresses? I think in terms of the things that people will be really focused on, those are the main ones. The readouts are obviously the key right now. Obviously, there are other readouts in the space that we’re all looking at. Compass being an important one. We do remain a shareholder in Compass. They have an interim readout that is also middle of this year. First quarter of next year, I believe, is when the totality of the so-called 005 study will read out. So again, that’s going to be a big one for the space, of course. Quotes have been lightly edited for clarity and style
Analysts’ Opinion of ATAI
Many brokerage firms have already submitted their reports for ATAI stocks, with H.C. Wainwright repeating the rating for ATAI by listing it as a “Buy.” The predicted price for ATAI in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on November 18, 2024 of the previous year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see ATAI reach a price target of $6. The rating they have provided for ATAI stocks is “Buy” according to the report published on April 03rd, 2024.
Loop Capital gave a rating of “Buy” to ATAI, setting the target price at $18 in the report published on November 01st of the previous year.
ATAI Trading at 65.17% from the 50-Day Moving Average
After a stumble in the market that brought ATAI to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.36% of gains for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATAI starting from Kirpekar Sahil, who sale 48,563 shares at the price of $1.35 back on Mar 21 ’25. After this action, Kirpekar Sahil now owns 115,636 shares of ATAI Life Sciences N.V, valued at $65,560 using the latest closing price.
Craig Kevin James, the Chief Medical Officer of ATAI Life Sciences N.V, sale 11,563 shares at $1.35 during a trade that took place back on Mar 21 ’25, which means that Craig Kevin James is holding 8,437 shares at $15,610 based on the most recent closing price.
Stock Fundamentals for ATAI
Current profitability levels for the company are sitting at:
- -53.12 for the present operating margin
- 0.88 for the gross margin
The net margin for ATAI Life Sciences N.V stands at -79.97. The total capital return value is set at -0.59. Equity return is now at value -62.43, with -50.86 for asset returns.
Based on ATAI Life Sciences N.V (ATAI), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -5.46. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -29.66.
Currently, EBITDA for the company is -145.33 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 258.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.07.
Conclusion
To sum up, ATAI Life Sciences N.V (ATAI) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
